Member Info for inanaco

i am not ....

But T cells are the same

“The combined therapy of GX-188E and Keytruda showed a safety profile similar to monotherapy of Keytruda,” Woo said. “The therapy significantly improved patients’ response rate to 42.3 percent. By showing clinical response in PD-L1 negative patients, too, the combined therapy proved its safety and effectiveness.

?? : KBR(http://www.koreabiomed.com)

Genexine ..... has set the bench mark ...

Just to explain why we dig deep into trials and understanding the mechanism of action ...

is because i have just added 500,000 shares using that knowledge of challenging myself to understand

or

you wait for results and pay the expected uplifted price ..........

Diggles did exactly what i have been doing .......... he put his Man (Prof) on the inside track and he backed the science ....

i suspect Redmile also did serious Due Divergence to ......

or you can walk around claiming its all to risky ... and invest in "sound stocks" ...

Banks ... opps!
BA ......... Opps!
RR..........Opps!

Covid and Scancell ...

just to point out to those reading the posts ......... we are NOT expecting 100 % response rate from SCIB1/Keytruda

its 55% ...............

Burbles Post fits into that criteria ...

i believe we have also had 3 patients receive benefit from Pd-1 after taking Scib1, thus would have memory

which is why i took a very considered look at the Genexine trial with keytruda

http://www.koreabiomed.com/news/articleView.html?idxno=8103

Buy on sound Knowledge ...

if proven it will not be 11p

I am an investor Ruck not a scientist ...

the fact that scientist "present" papers ... might give you a clue why we read them ...

well inflammation caused by SCIB1 will induce the cancer to express the PD-1 ligand, just because the cancer is baron of PD-1 does not mean that it cannot mount a response ... the key is to get the TIL into the cancer that maintain function high avidity t cells are capable of that .. and can dampen down any suppression by CD4 ... flipping the state to a TH1 ... pro inflammatory indeed that is why the SCIB1 vaccine includes CD4 helper

I became an authority on it ........ people challenged me

why would i need to challenge myself .. when i can read scientific papers ? Patents etc and pull of the relevant bits

when did Bermuda last ask you to read a patent .. ?

Think of it like this ......... Burble is switched on the biological process and understanding indeed has the paperwork .. has been in the share for years.....

How many times has Burble had to pull me up on my science posts ?

so that is how you justify investments .......... by understanding ..

so i will ask Burble can you answer this question

If SCIB1 induces potent T cells ...

and Keytruda works by binding and Blocking the PD-1 pathway on the T cell

with both drugs proved to work ....

can you show how Synergy is not possible .. ? what is the potential mechanism of failure ?

Knowlesi ... i had 500,000 shares at 10p ........ i started adding at 8p and below .. how have i got it wrong ? i have bought 500,000 sub 8p with the majority around 5p ...

of that original 500,000 ... 300,000 bought prior to the moditope RNS ... between 8 and 12 p

you live in cuckoo land

we are not the same Ivy ..

I challenge investments all the time by understanding what scancell is doing ..

hence i tipped you off on MTFB ...

Ivy i didn't sell at a loss or spend months attacking Scancell BOD

and out of the Blue you have become the "darling" of scancell ... ?

history history history

well that beat knowlesi attempt at 3p ... how did you do it .. ?

so why has it been going up since the 20th of July ...

nobody can find a negative ..........

isn't it great i don't have to deal with Drivel ...

Matt ... Moditope RNS (midday) .... 19p ... next stop 33p

Knowlesi

Posted in: SCLP

Posts: 2,439

Price: 4.90

No Opinion

RE: Volume 548k29 Nov 2019 14:42
5p breached - could be prime the bazooka time coming. Will we go lower than 3.6p...I think likely yes.

https://youtu.be/_HkL8GuU9_0